Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Short-term Investments (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Short-term Investments data on record, last reported at $51.0 million in Q2 2025.

  • For Q2 2025, Short-term Investments changed N/A year-over-year to $51.0 million; the TTM value through Jun 2025 reached $51.0 million, changed N/A, while the annual FY2024 figure was $73.7 million, 33.21% down from the prior year.
  • Short-term Investments reached $51.0 million in Q2 2025 per ASMB's latest filing, down from $67.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $139.6 million in Q2 2021 and bottomed at $29.5 million in Q1 2023.
  • Average Short-term Investments over 5 years is $80.3 million, with a median of $70.7 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: plummeted 61.2% in 2022, then soared 181.71% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $101.0 million in 2021, then tumbled by 61.2% to $39.2 million in 2022, then skyrocketed by 181.71% to $110.4 million in 2023, then plummeted by 33.21% to $73.7 million in 2024, then crashed by 30.87% to $51.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $51.0 million in Q2 2025, $67.6 million in Q1 2025, and $73.7 million in Q4 2024.